Apricus Biosciences, Inc. (“Apricus Bio” or the “Company”) (Nasdaq:APRI) (http://www.apricusbio.com) announced today that the submission of an abstract entitled, “Results of a Phase III Clinical Trial for Female Sexual Arousal Disorder (“FSAD”) with Femprox®, a Topical Alprostadil 0.4% Cream with a Novel Transdermal Delivery Technology,” was accepted as a moderated poster (#43) at the upcoming Sexual Medicine Society of Northern America (“SMSNA”) conference in Las Vegas, scheduled to take place November 10-13, 2011.
